We are live on ! Find out more
ACA

Acorn Capital Advisors Portfolio holdings

AUM $352M
1-Year Est. Return 299.18%
This Fund
S&P 500
This Quarter Est. Return
-14.57%
1 Year Est. Return
+299.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$150M
AUM Growth
-$35.9M
Cap. Flow
+$9.79M
Cap. Flow %
6.53%
Top 10 Hldgs %
80.39%
Holding
22
New
1
Increased
7
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
AURA icon
Aura Biosciences
AURA
+$4.47M
2
YMAB
Y-mAbs Therapeutics
YMAB
+$2.17M
3
CADL icon
Candel Therapeutics
CADL
+$1.74M
4
YARW
Yarrow Bioscience, Inc. Common Stock
YARW
+$810K
5
TRVI icon
Trevi Therapeutics
TRVI
+$686K

Top Sells

Rank Stock Value
1
MURA
Mural Oncology
MURA
+$59.7K
2
WHWK
Whitehawk Therapeutics
WHWK
+$20.1K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.28B
$27.7M 18.49%
1,131,501
– –
URGN icon
2
UroGen Pharma
URGN
$1.86B
$16.8M 11.18%
1,516,303
– –
YMAB
3
DELISTED
Y-mAbs Therapeutics
YMAB
$14.3M 9.56%
3,235,387
+373,562
+13% +$2.17M
TRVI icon
4
Trevi Therapeutics
TRVI
$2.59B
$13.5M 9%
2,144,844
+143,796
+7% +$686K
CADL icon
5
Candel Therapeutics
CADL
$733M
$12.2M 8.11%
2,152,252
+212,608
+11% +$1.74M
PBYI icon
6
Puma Biotechnology
PBYI
$404M
$11.7M 7.78%
3,940,052
– –
BCAX
7
Bicara Therapeutics
BCAX
$1.78B
$8.38M 5.59%
643,382
+1
+0% +$13
TARA icon
8
Protara Therapeutics
TARA
$220M
$5.45M 3.64%
1,279,800
– –
TERN
9
DELISTED
Terns Pharmaceuticals
TERN
$5.44M 3.63%
1,971,264
– –
OKUR
10
OnKure Therapeutics
OKUR
$154M
$5.12M 3.42%
1,439,674
– –
VSTM icon
11
Verastem
VSTM
$510M
$4.7M 3.13%
779,498
– –
HELP
12
Cybin Inc
HELP
$485M
$4.66M 3.11%
734,394
+1
+0% +$9
CRDF icon
13
Cardiff Oncology
CRDF
$66.5M
$4.53M 3.02%
1,442,308
– –
OPTN
14
DELISTED
OptiNose
OPTN
$3.88M 2.59%
422,814
+1
+0% +$6
WHWK
15
Whitehawk Therapeutics
WHWK
$190M
$2.03M 1.35%
1,139,363
-7,689
-0.7% -$20.1K
XFOR icon
16
X4 Pharmaceuticals
XFOR
$375M
$1.75M 1.17%
243,688
– –
MURA
17
DELISTED
Mural Oncology
MURA
$1.6M 1.07%
1,269,715
-16,364
-1% -$59.7K
AURA icon
18
Aura Biosciences
AURA
$725M
$1.45M 0.97%
+590,508
New +$4.47M
BCAB icon
19
BioAtla
BCAB
$5.46M
$1.41M 0.94%
80,641
– –
QTTB icon
20
Q32 Bio
QTTB
$466M
$1.33M 0.88%
803,425
– –
YARW
21
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$1.24M 0.83%
15,719
+6,580
+72% +$810K
ACRV icon
22
Acrivon Therapeutics
ACRV
$64.2M
$823K 0.55%
405,237
– –

Similar funds

PIC
PCJ Investment Counsel Toronto, Ontario, Canada $352M AUM 68.32% 1-Year Est. Return
HIA
HTG Investment Advisors New Canaan, Connecticut $352M AUM 17.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
EC
Elmind Capital New York $352M AUM
AW
Alaethes Wealth Glenbrook, Nevada $351M AUM 22.79% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
FWM
ForthRight Wealth Management Alpharetta, Georgia $353M AUM 12.98% 1-Year Est. Return
BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Acorn Capital Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Acorn Capital Advisors held 22 positions worth $150M, down 19% from $186M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Acorn Capital Advisors deployed $9.79M of net new capital in Q1 2025, opening 1 new position and adding to 7 existing holdings. Its largest new stake was Aura Biosciences: 590,508 shares worth $1.45M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Mural Oncology, an estimated $59.7K trimmed.

  • Acorn Capital Advisors's largest Q1 2025 buy was Aura Biosciences: 590,508 shares worth $1.45M.
  • Acorn Capital Advisors added most to Y-mAbs Therapeutics in Q1 2025, an estimated $2.17M increase.
  • Acorn Capital Advisors's biggest Q1 2025 reduction was Mural Oncology, cutting an estimated $59.7K.
  • Acorn Capital Advisors's ten largest holdings make up 80% of its $150M portfolio in Q1 2025.
  • Acorn Capital Advisors opened 1 new position and closed 0 in Q1 2025.
  • Acorn Capital Advisors's portfolio value fell 19% quarter-over-quarter to $150M.

Based on Acorn Capital Advisors's 13F filing for Q1 2025, filed 15 May 2025.